A case of prostatic adenocarcinoma with aberrant p63 expression: Presentation with detailed immunohistochemical study and FISH analysis

International Journal of Surgical Pathology

Volumn 19, Issue 1, 2011, Pages 131-136

  Baydar, Dilek Ertoy ^a   Kulac, Ibrahim ^a   Gurel, Bora ^b   De Marzo, Angelo ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

aberrant p63; FISH; prostatic adenocarcinoma; TMPRSS2 ERG translocation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN P63;

ADULT; ARTICLE; CASE REPORT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TMPRSS2 ERG GENE;

ADENOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 79551657658     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896910379478     Document Type: Article

References (21)

1. Oliai BR, Kahane H., Epstein JI Can basal cells be seen in adenocarcinoma of the prostate? An immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol. 2002 ; 26: 1151-1160.
2. Ali TZ, Epstein JI False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Am J Surg Pathol. 2008 ; 32: 1890-1895.
3. Parsons JK, Gage WR, Nelson WG, De Marzo AM p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001 ; 58: 619-624.
4. Osunkoya AO, Hansel DE, Sun X., Netto GJ, Epstein JI Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol. 2008 ; 32: 461-467.
5. Albadine R., Latour M., Toubaji A., et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol. 2009 ; 22: 1415-1422.
6. Begnami MD, Quezado M., Pinto P., Linehan WM, Merino M. Adenoid cystic/basal cell carcinoma of the prostate: review and update. Arch Pathol Lab Med. 2007 ; 131: 637-640.
7. McKenney JK, Amin MB, Srigley JR, et al. Basal cell proliferations of the prostate other than usual basal cell hyperplasia: a clinicopathologic study of 23 cases, including four carcinomas, with a proposed classification. Am J Surg Pathol. 2004 ; 28: 1289-1298.
8. Zellweger T., Ninck C., Bloch M., et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer. 2005 ; 113: 619-628.
9. Szostak MJ, Kaur P., Amin P., Jacobs SC, Kyprianou N. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol. 2001 ; 165: 2126-2130.
10. Tomlins SA, Rhodes DR, Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005 ; 310: 644-648.
11. Mehra R., Tomlins SA, Shen R., et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007 ; 20: 538-544.
12. Dai MJ, Chen LL, Zheng YB, et al. Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer [in Chinese]. Zhonghua Yi Xue Za Zhi. 2008 ; 88: 669-673.
13. Yegnasubramanian S., Kowalski J., Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004 ; 64: 1975-1986.
14. Dohn M., Zhang S., Chen X. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene. 2001 ; 20: 3193-3205.
15. Dietz S., Rother K., Bamberger C., Schmale H., Mössner J., Engeland K. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73. FEBS Lett. 2002 ; 525: 93-99.
16. Katoh I., Aisaki KI, Kurata SI, Ikawa S., Ikawa Y. p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene. 2000 ; 19: 3126-3130.
17. Okada Y., Osada M., Kurata S., et al. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation. Exp Cell Res. 2002 ; 276: 194-200.
18. Weber A., Bellmann U., Bootz F., Wittekind C., Tannapfel A. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. Int J Cancer. 2002 ; 99: 22-28. (Pubitemid 34273193)
19. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope. 2004 ; 114: 2063-2072.
20. Taniere P., Martel-Planche G., Saurin JC, et al. TP53 mutations amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe. Br J Cancer. 2001 ; 85: 721-726.
21. Parsons JK, Saria EA, Nakayama M., et al. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. Prostate. 2009 ; 69: 559-569.